Amplia Therapeutics Limited
INNMF
$0.1183
-$0.0067-5.36%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 745.50K | 774.40K | 471.30K | 463.60K | 659.10K |
| Total Revenue | 745.50K | 774.40K | 471.30K | 463.60K | 659.10K |
| Cost of Revenue | 43.80K | 45.50K | 23.80K | 23.40K | 108.70K |
| Gross Profit | 701.70K | 728.90K | 447.60K | 440.20K | 550.40K |
| SG&A Expenses | 443.80K | 461.00K | 447.50K | 440.20K | 469.70K |
| Depreciation & Amortization | 13.30K | 13.80K | 14.50K | 14.30K | 14.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.98M | 2.06M | 1.42M | 1.40M | 1.78M |
| Operating Income | -1.24M | -1.29M | -952.70K | -936.90K | -1.12M |
| Income Before Tax | -1.18M | -1.22M | -942.80K | -927.20K | -1.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.18M | -1.22M | -942.80K | -927.20K | -1.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.18M | -1.22M | -942.80K | -927.20K | -1.11M |
| EBIT | -1.24M | -1.29M | -952.70K | -936.90K | -1.12M |
| EBITDA | -1.24M | -1.28M | -938.10K | -922.60K | -1.12M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 360.72M | 360.72M | 253.70M | 253.70M | 194.01M |
| Average Diluted Shares Outstanding | 360.72M | 360.72M | 253.70M | 253.70M | 194.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |